Axsome Therapeutics AXSM underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 10 | 6 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 3 | 2 | 0 | 0 | 0 |
| 2M Ago | 6 | 3 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $129.06, along with a high estimate of $180.00 and a low estimate of $95.00. Observing a 0.41% increase, the current average has risen from the previous average price target of $128.53.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Axsome Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $107.00 | $107.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $107.00 | $107.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $180.00 | $180.00 |
| Ami Fadia | Needham | Maintains | Buy | $130.00 | $130.00 |
| Cerena Chen | Wells Fargo | Announces | Overweight | $140.00 | - |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $180.00 | $180.00 |
| Ashwani Verma | UBS | Lowers | Buy | $105.00 | $107.00 |
| Leonid Timashev | RBC Capital | Lowers | Outperform | $130.00 | $131.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Lowers | Buy | $180.00 | $190.00 |
| Jason Gerberry | B of A Securities | Raises | Buy | $106.00 | $95.00 |
| Ami Fadia | Needham | Maintains | Buy | $130.00 | $130.00 |
| Ami Fadia | Needham | Maintains | Buy | $130.00 | $130.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $107.00 | $107.00 |
| Leonid Timashev | RBC Capital | Maintains | Outperform | $131.00 | $131.00 |
| Ami Fadia | Needham | Announces | Buy | $130.00 | - |
| Jason Gerberry | B of A Securities | Lowers | Neutral | $95.00 | $97.00 |
| Graig Suvannavejh | Mizuho | Maintains | Buy | $106.00 | $106.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Axsome Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Axsome Therapeutics compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Axsome Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Axsome Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Axsome Therapeutics analyst ratings.
Get to Know Axsome Therapeutics Better
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Axsome Therapeutics: A Financial Overview
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Axsome Therapeutics showcased positive performance, achieving a revenue growth rate of 86.65% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -91.03%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Axsome Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -64.28%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Axsome Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -14.51%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Axsome Therapeutics's debt-to-equity ratio is below the industry average at 1.86, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Significance of Analyst Ratings Explained
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
